Literature DB >> 28331700

Docetaxel-induced Scleroderma in A Breast Cancer Patient: A Case Report.

Murat Özgür Kılıç1, Metin Yalaza1, Celal İsmail Bilgiç1, Cenap Dener1.   

Abstract

Paclitaxel and docetaxel are antineoplastic drugs derived from the yew tree, Taxus brevifolia. They are the members of the taxane family and act by inhibiting mitotic activity due to the suppression of microtubule depolymerization. They are used in the treatment of ovarian cancer, breast cancer, gastric cancer, small cell lung cancer, and head and neck cancer. In addition to side effects such as cardiotoxicity, neutropenia, arthralgia, and myalgia, they may also cause alopecia, urticaria, mucositis, acral erythema, pustular dermatitis, erythema multiforme, and scleroderma-like mucocutaneous lesions. Scleroderma is among the uncommon side effects of taxane antineoplastic agents. As was the case in few cases in literature, it usually begins with edematous changes in the proximal aspect of the extremities, and subsequently, sclerosis is developed in the skin. Scleroderma, which usually regresses with the discontinuation of the drug and with steroid therapy, may lead to severe contractions that require physical therapy and rehabilitation in some patients. In this paper, we presented a 60-year-old female patient in whom scleroderma developed because docetaxel chemotherapy for breast cancer because it is encountered rarely.

Entities:  

Keywords:  Taxoids; breast cancer; scleroderma

Year:  2015        PMID: 28331700      PMCID: PMC5351495          DOI: 10.5152/tjbh.2015.1879

Source DB:  PubMed          Journal:  J Breast Health        ISSN: 1306-0945


  16 in total

1.  Scleroderma induced by paclitaxel.

Authors:  Joanna Vitfell Pedersen; Signe Jensen; Anders Krarup-Hansen; Lene Riis
Journal:  Acta Oncol       Date:  2010-08       Impact factor: 4.089

Review 2.  Taxane-induced scleroderma.

Authors:  M Itoh; K Yanaba; T Kobayashi; H Nakagawa
Journal:  Br J Dermatol       Date:  2007-02       Impact factor: 9.302

3.  Limited cutaneous systemic sclerosis induced by paclitaxel in a patient with breast cancer.

Authors:  Tamihiro Kawakami; Yuko Tsutsumi; Yoshinao Soma
Journal:  Arch Dermatol       Date:  2009-01

4.  Cutaneous fibrosis induced by docetaxel: a case report.

Authors:  M G Cleveland; B S Ajaikumar; R Reganti
Journal:  Cancer       Date:  2000-03-01       Impact factor: 6.860

5.  Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer.

Authors:  R De Angelis; L Bugatti; A Cerioni; P Del Medico; G Filosa
Journal:  Clin Rheumatol       Date:  2003-02       Impact factor: 2.980

6.  Erythema multiforme major following docetaxel.

Authors:  Christina Moisidis; Volker Möbus
Journal:  Arch Gynecol Obstet       Date:  2004-07-09       Impact factor: 2.344

7.  Scleroderma-like drug reaction to paclitaxel (Taxol).

Authors:  S Läuchli; R M Trüeb; M Fehr; J Hafner
Journal:  Br J Dermatol       Date:  2002-09       Impact factor: 9.302

8.  Photodistributed erythema multiforme: paclitaxel-related, photosensitive conditions in patients with cancer.

Authors:  Philip R Cohen
Journal:  J Drugs Dermatol       Date:  2009-01       Impact factor: 2.114

Review 9.  Paclitaxel: a new antimitotic chemotherapeutic agent.

Authors:  G E Gotaskie; B F Andreassi
Journal:  Cancer Pract       Date:  1994 Jan-Feb

10.  Cutaneous reaction associated with weekly docetaxel administration.

Authors:  Lita Chew; Vivianne Shih Lee Chuen
Journal:  J Oncol Pharm Pract       Date:  2008-08-27       Impact factor: 1.809

View more
  2 in total

Review 1.  Paclitaxel-induced diffuse scleroderma with possible scleroderma-renal crisis: a case report and literature review of taxanes-induced scleroderma.

Authors:  Thanika Ketpueak; Wanitcha Chanloung; Kittiya Na Nan; Chontara Pongsananurak; Nuntana Kasitanon; Worawit Louthrenoo
Journal:  Clin Rheumatol       Date:  2022-09-09       Impact factor: 3.650

2.  Unusually thickened skin and neuropathy in a patient with prostate cancer.

Authors:  Albert E Zhou; Karl M Hoegler; Marcia S Driscoll
Journal:  JAAD Case Rep       Date:  2021-06-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.